Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Halozyme TherapeuticsHALO -0.01%93 Debt-to-EBITDA is 2.44 as of Mar. 2026, which is 2% below its 10-year median of 2.48. GuruFocus rates HALO with a GF Score™ of 93/100 and a GF Value™ of $92.38 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 296 Biotechnology companies, Halozyme Therapeutics ranks worse than 71.96% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Halozyme Therapeutics's Debt-to-EBITDA or its related term are showing as below:
HALO'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -7.12 Med: 2.48 Max: 4.77
Current: 3.44
During the past 13 years, the highest Debt-to-EBITDA Ratio of Halozyme Therapeutics was 4.77. The lowest was -7.12. And the median was 2.48.
HALO's Debt-to-EBITDA is ranked worse than 71.96% of 296
companies
in the Biotechnology industry
Industry Median: 1.185
vs HALO: 3.44
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Halozyme Therapeutics Debt-to-EBITDA Related Terms
Halozyme Therapeutics Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Halozyme Therapeutics's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HALO vs NUVL, KRYS, IONS: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Halozyme Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Halozyme Therapeutics Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Halozyme Therapeutics's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Halozyme Therapeutics (HALO) has a Debt-to-EBITDA of 2.44 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Halozyme Therapeutics. This is near median its historical median of 2.48. According to the industry distribution chart, Halozyme Therapeutics ranks #213 out of 296 companies in the Biotechnology industry, placing it in the top 72%.
Is Halozyme Therapeutics' Debt-to-EBITDA too high?
Halozyme Therapeutics' current Debt-to-EBITDA of 2.44 is near median its 10-year median of 2.48. The Biotechnology industry median Debt-to-EBITDA is 1.19. Halozyme Therapeutics' value of 2.44 is 105.9% above this industry median. Based on the distribution chart, Halozyme Therapeutics ranks #213 out of 296 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Halozyme Therapeutics has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' Debt-to-EBITDA compare to NUVL and KRYS?
According to the Biotechnology industry distribution chart, Halozyme Therapeutics ranks #213 out of 296 companies for Debt-to-EBITDA. This places Halozyme Therapeutics in the lower half of its industry. The industry median Debt-to-EBITDA is 1.19. Halozyme Therapeutics' value of 2.44 is 105.9% above this benchmark. While the company's 10-year median is 2.48 vs. the industry median of 1.19, Halozyme Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.19, based on 296 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Halozyme Therapeutics's current Debt-to-EBITDA of 2.44 is 105.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Halozyme Therapeutics. For the Biotechnology industry, the median Debt-to-EBITDA is 1.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Halozyme Therapeutics's current Debt-to-EBITDA is 2.44, which is near median its own 10-year median of 2.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (HALO) is currently considered Modestly Undervalued. The stock's GF Value™ is $92.38, compared to a current price of $82.27 — trading 10.9% below its estimated fair value. The current Debt-to-EBITDA is 2.44, which is near median its 10-year median of 2.48 and 105.9% above the Biotechnology industry median of 1.19. Halozyme Therapeutics' overall GF Score™ is 93/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Halozyme Therapeutics (HALO), the current Debt-to-EBITDA is 2.44 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Halozyme Therapeutics (HALO) Overvalued in 2026?
Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be undervalued.
The current stock price of $82.27 is trading 10.9% below its estimated GF Value™ of $92.38.
GuruFocus considers Halozyme Therapeutics to be Modestly Undervalued.
Key valuation signals for HALO:
Debt-to-EBITDA: 2.44 (near median its 10-year median of 2.48)
GF Value™: $92.38 vs. price of $82.27 (10.9% below fair value)
Industry Position: 105.9% above the Biotechnology median (#213 of 296)
No single metric tells the full story. See the HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
93GF Score
Get the complete analysis for HALO
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HALO has been successfully added to your 
